TFEB and metabolic dysfunction-associated steatotic liver disease: Furthermore, activating TFEB by ezetimibe and tetrahalose can inhibit the NRLP3-dependent IL-1β production and reduce NAFLD lesions (Kim et al., 2017; Sergin et al., 2017).